Gentuximab clinical trials
How each study uses Gentuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Gentuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedPhase 1/2Changchun GeneScience Pharmaceutical Co., Ltd.NCT04053205Written as GentuximabHow we know
- Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.Status unknownPhase 3Changchun GeneScience Pharmaceutical Co., Ltd.NCT05919381Written as Gentuximab InjectionHow we know
- A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLCStatus unknownPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT05223595Written as GentuximabHow we know
- Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in ChinaStatus unknownPhase 1Changchun GeneScience Pharmaceutical Co., Ltd.NCT03313219Written as Gentuximab InjectionHow we know